Evidence map›Paper›PMID 40911810›Full record

Observational studyJornal brasileiro de nefrologia

Acute kidney disease in patients with COVID-19. A prospective, multicenter, multinational study in Latin America.

Raúl Lombardi, Alejandro Ferreiro, Yanissa Venegas, Mariana Pereira, Cristina Carlino, Rolando Claure-Del Granado, Daniela Ponce, Daniel Molina, Agustina Zinoveev

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Jornal brasileiro de nefrologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Unmasking the presentation of AKD in COVID-19.Jornal brasileiro de nefrologia
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Raúl LombardiUniversidad de la República, Facultad de Medicina, Centro de Nefrología, Montevideo, Uruguay.ORCID 0000-0002-2398-794X
Alejandro FerreiroUniversidad de la República, Facultad de Medicina, Centro de Nefrología, Montevideo, Uruguay.ORCID 0000-0001-6819-8058
Yanissa VenegasUniversidad Peruana Cayetano Heredia, Hospital Nacional Arzobispo Loayza, Lima, Perú.ORCID 0000-0003-1141-0710
Mariana PereiraHospital do Servidor Público do Estado de São Paulo, São Paulo, SP, Brazil.ORCID 0000-0001-5107-3718
Cristina CarlinoHospital Provincial de Rosario, Nefrología, Santa Fe, Argentina.ORCID 0000-0002-8063-4120
Rolando Claure-Del GranadoCaja Nacional de Salud, Hospital Obrero No 2, División de Nefrología, Cochabamba, Bolivia.ORCID 0000-0002-8163-3779
Daniela PonceUniversidade Estadual Paulista, Departamento de Nefrologia, Botucatu, SP, Brazil.ORCID 0000-0002-6178-6938
Daniel MolinaCaja Petrolera de Salud, Santa Cruz, Bolivia.ORCID 0000-0003-0551-9162
Agustina ZinoveevCentro de Asistencia del Sindicato Médico del Uruguay (CASMU), Institución de Asistencia Médica Privada de Profesionales sin fines de lucro (IAMPP), Departamento de Nefrología, Montevideo, Uruguay.ORCID 0009-0007-0877-4560

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAcute kidney disease (AKD) is defined as functional and/or structural abnormalities of kidneys with health implications and a duration of ≤90 days. This study aimed to evaluate AKD as a more appropriate approach to these conditions for which we used a cohort of COVID-19 patients in whom kidney impairment is expressed by proteinuria and/or loss of function.

methodsObservational, prospective, longitudinal, multinational cohort study conducted across five Latin American countries. Adult patients with diagnosis of COVID-19 were included. Upon hospital admission, urinalysis or urine strip test was performed. If protein was not detected, a follow-up search was conducted five days later. Patients were classified in four AKD categories: non-kidney disease, proteinuria only, acute kidney injury (AKI) only, and proteinuria and AKI.

resultsThree hundred and sixty patients were included. AKD was present in 273 (75.8%), of whom 142 (52.0%) had only proteinuria, 11 (4.1%) had AKI without proteinuria, and 120 (43.9%) had both proteinuria and AKI. Overall, proteinuria with or without AKI was present in 262 patients (72.8%). AKI with or without proteinuria occurred in 131 patients (36.4%). AKI was mainly severe, non-oliguric, and hospital-acquired. In-hospital mortality increased with the severity of AKD: non-kidney disease 9.5%, proteinuria only 22.8%, AKI only 56.7%, and proteinuria plus AKI 53.0% (p = 0.001).

conclusionsOur data endorse a comprehensive approach based on the concept of AKD. This integrative approach, encompassing the structural and functional continuum of AKI, AKD, and CKD, enables timely interventions and the implementation of preventive and therapeutic strategies.

Indexed as

Acute Kidney InjuryCOVID-19ProteinuriaAdultAgedFemaleHumansLatin AmericaLongitudinal StudiesMaleMiddle AgedProspective StudiesSARS-CoV-2

Identifiers

PMID40911810
PMCPMC12448115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.